Comparing six antihypertensive medication classes for preventing new-onset diabetes mellitus among hypertensive patients: a network meta-analysis

Journal of Cellular and Molecular Medicine

Volumn 21, Issue 9, 2017, Pages 1742-1750

  Yang, Yang ^a   Xu, Huilan ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

angiotensin II converse enzyme inhibitors; angiotensin II receptor blockers; calcium channel blockers; diuretic; hypertension; new onset diabetes; blockers

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; HYDROCHLOROTHIAZIDE;

ARTICLE; BLOOD PRESSURE; COMPARATIVE STUDY; DIABETES MELLITUS; HUMAN; HYPERTENSION; INCIDENCE; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; PROBABILITY;

ANTIHYPERTENSIVE AGENTS; DIABETES MELLITUS; HUMANS; INCIDENCE; PROBABILITY;

EID: 85013659458     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.13096     Document Type: Article

References (66)

1. Chowdhury EK, Ademi Z, Moss JR, et al. Cost-utility of angiotensin-converting enzyme inhibitor-based treatment compared with thiazide diuretic-based treatment for hypertension in elderly Australians considering diabetes as comorbidity. Medicine. 2015; 94: e590.
2. Liou YS, Chen HY, Tien L, et al. Antihypertensive drug use and new-onset diabetes in female patients with coronary artery disease: a population-based longitudinal cohort study. Medicine (Baltimore). 2015; 94: e1495.
3. Palepu S, Prasad GV. New-onset diabetes mellitus after kidney transplantation: current status and future directions. World J Diabetes. 2015; 6: 445–55.
4. Andraws R, Brown DL. Effect of inhibition of the renin-angiotensin system on development of type 2 diabetes mellitus (meta-analysis of randomized trials). Am J Cardiol. 2007; 99: 1006–12.
5. Hassanin A, Malek HA. Effect of renin inhibition on adipokines in diabetic rats. Pak J Pharm Sci. 2014; 27: 767–72.
6. Vardeny O, Uno H, Braunwald E, et al. Opposing effects of beta blockers and angiotensin-converting enzyme inhibitors on development of new-onset diabetes mellitus in patients with stable coronary artery disease. Am J Cardiol. 2011; 107: 1705–9.
7. Liou YS, Ma T, Tien L, et al. The relationship between antihypertensive combination therapies comprising diuretics and/or beta-blockers and the risk of new-onset diabetes: a retrospective longitudinal cohort study. Hypertens Res. 2009; 32: 496–9.
8. Tocci G, Paneni F, Palano F, et al. Angiotensin-converting enzyme inhibitors, angiotensin ii receptor blockers and diabetes: a meta-analysis of placebo-controlled clinical trials. Am J Hypertens. 2011; 24: 582–90.
9. Geng DF, Jin DM, Wu W, et al. Angiotensin converting enzyme inhibitors for prevention of new-onset type 2 diabetes mellitus: a meta-analysis of 72,128 patients. Int J Cardiol. 2013; 167: 2605–10.
10. Song HF, Wang S, Li HW. Effect of angiotensin receptor blockers in the prevention of type 2 diabetes and cardiovascular events: a meta-analysis of randomized trials. Chin Med J. 2012; 125: 1804–10.
11. Ricci F, Di Castelnuovo A, Savarese G, et al. Ace-inhibitors versus angiotensin receptor blockers for prevention of events in cardiovascular patients without heart failure - a network meta-analysis. Int J Cardiol. 2016; 217: 128–34.
12. McMurray JJ, Holman RR, Haffner SM, et al. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med. 2010; 362: 1477–90.
13. Ahmad MA, Kapur P, Khanam R, et al. Comparative effect of antihypertensive therapy on blood glucose level in hypertensive patients in an Indian population. Drug Res (Stuttg). 2014; 64: 276–80.
14. Garcia-Egido A, Andrey JL, Puerto JL, et al. Beta-blocker therapy and prognosis of heart failure patients with new-onset diabetes mellitus. Int J Clin Pract. 2015; 69: 550–9.
15. Karnes JH, Gong Y, Arwood MJ, et al. Alteration in fasting glucose after prolonged treatment with a thiazide diuretic. Diabetes Res Clin Pract. 2014; 104: 363–9.
16. Abuissa H, Jones PG, Marso SP, et al. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials. J Am Coll Cardiol. 2005; 46: 821–6.
17. Bangalore S, Kumar S, Wetterslev J, et al. Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147 020 patients from randomised trials. BMJ. 2011; 342: d2234.
18. Bangalore S, Parkar S, Grossman E, et al. A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. Am J Cardiol. 2007; 100: 1254–62.
19. Cheung BMY, Cheung GTY, Lauder IJ, et al. Meta-analysis of large outcome trials of angiotensin receptor blockers in hypertension. J Hum Hypertens. 2006; 20: 37–43.
20. Geng DF, Jin DM, Wu W, et al. Angiotensin receptor blockers for prevention of new-onset type 2 diabetes: a meta-analysis of 59,862 patients. Int J Cardiol. 2012; 155: 236–42.
21. Gillespie EL, White CM, Kardas M, et al. The impact of ace inhibitors or angiotensin ii type 1 receptor blockers on the development of new-onset type 2 diabetes. Diabetes Care. 2005; 28: 2261–6.
22. Mason JM, Dickinson HO, Nicolson DJ, et al. The diabetogenic potential of thiazide-type diuretic and beta-blocker combinations in patients with hypertension. J Hypertens. 2005; 23: 1777–81.
23. Saha SA, Molnar J, Arora RR. Tissue ace inhibitors for secondary prevention of cardiovascular disease in patients with preserved left ventricular function: a pooled meta-analysis of randomized placebo-controlled trials. J Cardiovasc Pharmacol Ther. 2007; 12: 192–204.
24. Savarese G, Costanzo P, Cleland JGF, et al. A meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure. J Am Coll Cardiol. 2013; 61: 131–42.
25. Snedecor SJ, Ph D, Patel DA, et al. From pairwise to network meta-analyses. In: Biondi-Zoccai G, editor. 2014. pp. 21–41.
26. Jackson D, White IR, Thompson SG. Extending dersimonian and laird's methodology to perform multivariate random effects meta-analyses. Stat Med. 2010; 29: 1282–97.
27. Day NE, Byar DP. Testing hypotheses in case-control studies–equivalence of mantel-haenszel statistics and logit score tests. Biometrics. 1979; 35: 623–30.
28. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21: 1539–58.
29. Braunwald E, Domanski MJ, Fowler SE, et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med. 2004; 351: 2058–68.
30. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian cardiac outcomes trial-blood pressure lowering arm (ascot-bpla): a multicentre randomised controlled trial. Lancet. 2005; 366: 895–906.
31. Fox KM, Investigators EUtOrocewPiscAd. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the Europa study). Lancet. 2003; 362: 782–8.
32. Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the charm-alternative trial. Lancet. 2003; 362: 772–6.
33. Group NS, McMurray JJ, Holman RR, et al. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med. 2010; 362: 1477–90.
34. Investigators DT, Bosch J, Yusuf S, et al. Effect of ramipril on the incidence of diabetes. N Engl J Med. 2006; 355: 1551–62.
35. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the value randomised trial. Lancet. 2004; 363: 2022–31.
36. Lindholm LH, Ibsen H, Dahlof B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the losartan intervention for endpoint reduction in hypertension study (life): a randomised trial against atenolol. Lancet. 2002; 359: 1004–10.
37. Lithell H, Hansson L, Skoog I, et al. The study on cognition and prognosis in the elderly (scope): principal results of a randomized double-blind intervention trial. J Hypertens. 2003; 21: 875–86.
38. McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the charm-added trial. Lancet. 2003; 362: 767–71.
39. Party MRCW. Mrc trial of treatment of mild hypertension: principal results. Medical research council working party. Br Med J (Clin Res Ed) 1985; 291: 97–104.
40. Officers A, Coordinators for the ACRGTA, Lipid-Lowering Treatment to Prevent Heart Attack T. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (allhat). JAMA. 2002; 288: 2981–97.
41. Ogihara T, Nakao K, Fukui T, et al. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial. Hypertension. 2008; 51: 393–8.
42. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The international verapamil-trandolapril study (invest): a randomized controlled trial. JAMA. 2003; 290: 2805–16.
43. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the charm-overall programme. Lancet. 2003; 362: 759–66.
44. Rouleau JL, Warnica WJ, Baillot R, et al. Effects of angiotensin-converting enzyme inhibition in low-risk patients early after coronary artery bypass surgery. Circulation. 2008; 117: 24–31.
45. Telmisartan Randomised AssessmeNt Study in ACEiswcDI, Yusuf S, Teo K, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008; 372: 1174–83.
46. Vermes E, Ducharme A, Bourassa MG, et al. Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the studies of left ventricular dysfunction (solvd). Circulation. 2003; 107: 1291–6.
47. Wilhelmsen L, Berglund G, Elmfeldt D, et al. Beta-blockers versus diuretics in hypertensive men: main results from the happhy trial. J Hypertens. 1987; 5: 561–72.
48. Wing LM, Reid CM, Ryan P, et al. A comparison of outcomes with angiotensin-converting–enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med. 2003; 348: 583–92.
49. Yusuf S, Diener HC, Sacco RL, et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med. 2008; 359: 1225–37.
50. Yusuf S, Gerstein H, Hoogwerf B, et al. Ramipril and the development of diabetes. JAMA. 2001; 286: 1882–5.
51. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the charm-preserved trial. Lancet. 2003; 362: 777–81.
52. Alderman MH. New onset diabetes during antihypertensive therapy. Am J Hypertens. 2008; 21: 493–9.
53. Virk SA, Donaghue KC, Wong TY, et al. Interventions for diabetic retinopathy in type 1 diabetes: systematic review and meta-analysis. Am J Ophthalmol. 2015; 160: e4.
54. Underwood PC, Adler GK. The renin angiotensin aldosterone system and insulin resistance in humans. Curr Hypertens Rep. 2013; 15: 59–70.
55. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006; 444: 840–6.
56. Mancia G, Grassi G, Zanchetti A. New-onset diabetes and antihypertensive drugs. J Hypertens. 2006; 24: 3–10.
57. Chowdhury EK, Owen A, Ademi Z, et al. Short- and long-term survival in treated elderly hypertensive patients with or without diabetes: findings from the second Australian national blood pressure study. Am J Hypertens. 2014; 27: 199–206.
58. Gupta AK, Dahlof B, Dobson J, et al. Determinants of new-onset diabetes among 19,257 hypertensive patients randomized in the Anglo-Scandinavian cardiac outcomes trial–blood pressure lowering arm and the relative influence of antihypertensive medication. Diabetes Care. 2008; 31: 982–8.
59. Scheen AJ. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials. Diabetes Metab. 2004; 30: 487–96.
60. Basile JN. Antihypertensive therapy, new-onset diabetes, and cardiovascular disease. Int J Clin Pract. 2009; 63: 656–66.
61. Seravalle G, Brambilla G, Pizzalla DP, et al. Differential effects of enalapril-felodipine versus enalapril-lercanidipine combination drug treatment on sympathetic nerve traffic and metabolic profile in obesity-related hypertension. J Am Soc Hypertens. 2016; 10: 244–51.
62. Roush GC, Sica DA. Diuretics for hypertension: a review and update. Am J Hypertens. 2016; 29: 1130–1137.
63. Vinereanu D, Dulgheru R, Magda S, et al. The effect of indapamide versus hydrochlorothiazide on ventricular and arterial function in patients with hypertension and diabetes: results of a randomized trial. Am Heart J. 2014; 168: 446–56.
64. Costanzo P, Perrone-Filardi P, Petretta M, et al. Calcium channel blockers and cardiovascular outcomes: a meta-analysis of 175,634 patients. J Hypertens. 2009; 27: 1136–51.
65. Yamamoto Y, Sonoyama K, Matsubara K, et al. The status of hypertension management in Japan in 2000. Hypertens Res. 2002; 25: 717–25.
66. Taylor EN, Hu FB, Curhan GC. Antihypertensive medications and the risk of incident type 2 diabetes. Diabetes Care. 2006; 29: 1065–70.